Zobrazeno 1 - 10 of 33 pro vyhledávání: '"Alain Gendron"'
1
Akademický článek
Serotonin Transporter mRNA Expression Is Reduced in the Peripheral Blood Mononuclear Cells of Subjects with Major Depression but Normal in Fibromyalgia
Autor: Gaël Villanueva-Charbonneau, Stéphane Potvin, Serge Marchand, Alexander McIntyre, Diane McIntosh, Alain Bissonnette, Alain Gendron, Charles-Édouard Giguère, Marie-Ève Koué, Édouard Kouassi
Publikováno v: Brain Sciences, Vol 13, Iss 10, p 1485 (2023)
Background: Fibromyalgia (FM) and major depression disorder (MDD) frequently co-occur. Both disorders may share common serotonergic alterations, although there is less evidence of such alterations in FM. It is also unclear as to whether these alterat
Externí odkaz: https://doaj.org/article/9e75151b72024e68971552094b28f612
Zobrazit plný text záznamu
4
Akademický článek
Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data
Autor: Don Husereau, Jason Goodfield, Richard Leigh, Richard Borrelli, Michel Cloutier, Alain Gendron
Publikováno v: Allergy, Asthma & Clinical Immunology, Vol 14, Iss 1, Pp 1-9 (2018)
Abstract Background Stratification of patients with severe asthma by blood eosinophil counts predicts responders to anti-interleukin (IL)-5 (mepolizumab and reslizumab) and anti-IL-5 receptor α (benralizumab) therapies. This study characterized pati
Externí odkaz: https://doaj.org/article/b2ec169eb79d4eecb72352ab5b9e224d
Zobrazit plný text záznamu
5
Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada
Autor: Jelena Ivanovic, Alain Gendron, Michelle Erdmann, Jason K Lee, Atif Kukaswadia, Aren Fischer, Suvina Amin
Publikováno v: Patient Preference and Adherence. 14:725-735
Background Omalizumab is a treatment option for pediatric and adult patients with moderate to severe allergic asthma poorly controlled with standard inhaled therapies. Clinical trials and observational studies have demonstrated the efficacy of omaliz
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e8d4f50a06da999a1e4b0514cabc4c8c
https://doi.org/10.2147/ppa.s248324
Zobrazit plný text záznamu
9
Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study
Autor: Lawrence Mbuagbaw, Alain Gendron, Jason K Lee, Stephen G Noorduyn, Michelle Knutson, Niroshan Sriskandarajah
Publikováno v: ERJ Open Research
article-version (VoR) Version of Record
ERJ Open Research, Vol 7, Iss 1 (2021)
Asthma is a chronic inflammatory condition that affects 3.8 million Canadians and nearly 65 000 acute asthma exacerbations occur each year [1–4]. Left untreated, asthma can lead to increasing mortality and morbidity [2, 5, 6]. Economically, the pro
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd15ece6dde51d58f8733f6e136f5209
http://europepmc.org/articles/PMC8005685
Zobrazit plný text záznamu
10
Real-world treatment patterns of benralizumab therapy for patients with severe asthma
Autor: Karissa Johnston, Kathy M Osenenko, Niroshan Sriskandarajah, Stephen G Noorduyn, Alain Gendron
Publikováno v: Epidemiology.
Introduction: As many as 8% of patients with asthma in Canada have severe disease (Asthma Society of Canada, 2014). Patients with severe, eosinophilic asthma may benefit from a biologic therapy to improve asthma control. Benralizumab is an anti–IL-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4f9f211c59b612ab14b24d7d70bca272
https://doi.org/10.1183/13993003.congress-2020.4646
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje